|
|
 |
|
Viewing report
|
|
|
|
HIV-Associated Lipodystrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, June 2011, Pages: 61
HIV-Associated Lipodystrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
Industry analysis specialist, GlobalData, has released its new report, “HIV-Associated Lipodystrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information on the global HIV-associated lipodystrophy (HAL) therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global HAL therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global HAL sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData expects the HAL therapeutics market to value $209.8m by 2011, and forecasts growth of 37.1% per year for the next six years, to reach $1,392.5m by 2017. Such high growth can be attributed to the approval of the first FDA approved pharmacologic drug, Egrifta, in the otherwise dormant HIV associated lipodytsrophy therapeutics market in November 2010. The increasing awareness of HAL among HIV patients on highly active antiretroviral therapy (HAART) is expected to stimulate future market growth, by causing an increase in the treatment seeking population. So far, only off-label drugs were available for use for the treatment of HIV-associated lipodystrophy, and certain procedures such as injectable fillers and surgery were also available for the symptomatic relief of HIV-associated lipodystrophy. Currently, Egrifta is only approved in the US; however Theratechnologies applied for European Medicines Agency (EMEA) approval in Europe through its partner Ferrer International S.A in June, 2011. Egrifta is expected to enjoy its patent exclusivity until 2022. Egrifta is the first pharmacologic drug that reduces excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. There is no molecule in the late stage of pipeline for HAL expected to significantly influence the future HAL therapeutics market. All the molecules are still in the early phases of clinical development and are university or institute sponsored. Previously, the lack of specific, approved therapies for the treatment of HAL proved a barrier to the growth of the HAL therapeutics market.
Scope
The report provides information on the key drivers and challenges of the HAL therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) HAL therapeutics market revenue data for 2005–2010, and 2011–2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as growth hormones, growth hormone releasing factor regulator and insulin sensitizer and recombinant human growth hormone and insulin sensitizer.
- Analysis of the current and future competition in the seven key countries of the HAL therapeutics market. Theratechnologies, Inc., they key market player, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the HAL therapeutics market.
- Analysis of key recent licensing and partnership agreements in HAL therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HAL therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global HAL therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global HAL therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
